CorMedix (NASDAQ:CRMD) Price Target Raised to $14.00 at Royal Bank Of Canada

CorMedix (NASDAQ:CRMD) had its price target hoisted by Royal Bank Of Canada from $13.00 to $14.00 in a report released on Friday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

A number of other brokerages also recently commented on CRMD. Leerink Partners raised their target price on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of CorMedix in a report on Monday, April 27th. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Needham & Company LLC raised their price objective on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Finally, Citizens Jmp restated a “market outperform” rating and set a $19.00 price objective on shares of CorMedix in a research note on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, CorMedix currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

CorMedix Stock Down 7.4%

Shares of NASDAQ:CRMD opened at $7.54 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.74 and a current ratio of 2.97. CorMedix has a 1 year low of $6.13 and a 1 year high of $14.96. The stock has a market capitalization of $591.51 million, a P/E ratio of 3.52 and a beta of 1.50. The stock has a 50-day simple moving average of $8.14 and a 200-day simple moving average of $7.65.

CorMedix (NASDAQ:CRMD) last posted its earnings results on Thursday, August 13th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. The firm had revenue of $101.93 million during the quarter, compared to the consensus estimate of $96.04 million. CorMedix had a net margin of 40.49% and a return on equity of 41.90%. Equities analysts forecast that CorMedix will post 0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Financial Management Professionals Inc. acquired a new stake in CorMedix during the 4th quarter valued at $25,000. Comerica Bank lifted its holdings in CorMedix by 454.6% in the 3rd quarter. Comerica Bank now owns 2,690 shares of the company’s stock worth $31,000 after buying an additional 2,205 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in CorMedix in the 2nd quarter valued at about $42,000. Kestra Advisory Services LLC purchased a new position in CorMedix in the 4th quarter valued at about $49,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in CorMedix by 666.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock valued at $51,000 after buying an additional 3,813 shares during the last quarter. 34.18% of the stock is owned by institutional investors and hedge funds.

Key CorMedix News

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q2 results exceeded expectations: CorMedix reported earnings of $0.29 per share versus the $0.28 consensus estimate and revenue of $101.9 million, ahead of expectations near $96.0 million. Net income was $26.0 million and adjusted EBITDA was $58.7 million. CorMedix Second-Quarter Results
• Positive Sentiment: DefenCath and Melinta drove growth: Management cited solid DefenCath utilization and contributions from the Melinta portfolio as key factors behind the revenue beat, supporting the company’s commercial growth story. CRMD Q2 Earnings and Sales Beat
• Positive Sentiment: Profitability outlook improved: CorMedix maintained its fiscal 2026 revenue guidance of $325 million to $345 million, approximately in line with the $334.7 million analyst consensus, while raising its adjusted EBITDA guidance. The company also expects a supplemental filing for its fungal disease treatment by the third quarter, adding a potential pipeline catalyst. CorMedix Supplemental Filing Outlook
• Positive Sentiment: Analyst support strengthened: Royal Bank of Canada raised its price target from $13 to $14 and assigned an “outperform” rating. Other brokerages collectively maintain a “moderate buy” recommendation. RBC Price Target Update
• Neutral Sentiment: Guidance remains broadly aligned with expectations: Although the revenue outlook was maintained rather than raised, the higher EBITDA guidance indicates improving operating leverage and margins. Investors will likely focus on DefenCath adoption and execution against the second-half forecast.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.